FAQ on Soligenix Inc.'s Efforts in Addressing Rare Diseases with SGX945

What is Behçet’s disease and why is it significant?

Behçet’s disease is a rare autoimmune illness with genetic and environmental components, causing severe symptoms in young adulthood that can lead to serious complications like blindness, significantly affecting quality of life despite existing treatments.

How is Soligenix Inc. addressing the treatment gap for Behçet’s disease?

Soligenix is developing SGX945, a synthetic peptide designed to modulate the body’s innate immune response, enhancing inflammation resolution and tissue healing without immune suppression, as shown in preclinical studies.

What is SGX945 and how does it work?

SGX945 is an investigational drug by Soligenix that enhances the resolution of inflammation and promotes tissue healing without suppressing the immune system, targeting the unmet needs in treating Behçet’s disease.

What other conditions is Soligenix targeting with its pipeline?

Soligenix’s pipeline includes treatments for cutaneous T-cell lymphoma, psoriasis, inflammatory diseases like oral mucositis in head and neck cancer, and vaccine programs for ricin toxin, filoviruses, and COVID-19.

Who is involved in the development of SGX945?

Soligenix Inc., a late-stage biopharmaceutical company focused on rare diseases with unmet medical needs, is developing SGX945 as part of its Specialized BioTherapeutics business segment.

Where can I find more information about Soligenix and its developments?

More information is available on Soligenix’s website at www.Soligenix.com and updates relating to SNGX are in the company’s newsroom at https://ibn.fm/SNGX.

What are the implications of SGX945 for Behçet’s disease patients?

SGX945 offers the potential for more targeted and effective therapy for Behçet’s disease, aiming to reduce inflammation and accelerate healing without the adverse effects associated with current treatments.

How does SGX945 compare to current treatments for Behçet’s disease?

Unlike current treatments that may have adverse effects and do not prevent flares, SGX945 aims to modulate the immune response more effectively, promoting healing without immune suppression.

What is the significance of Soligenix’s Public Health Solutions business segment?

This segment focuses on developing vaccines for ricin toxin, filoviruses, and COVID-19, supported by government grants and contracts, utilizing Soligenix’s proprietary heat stabilization technology, ThermoVax®.